Attached files

file filename
EX-99.4 - EXHIBIT 99.4 - HOOPER HOLMES INCexhibit994proformas.htm
EX-99.3 - EXHIBIT 99.3 - HOOPER HOLMES INCexhibit993provantfinancial.htm
EX-99.2 - EXHIBIT 99.2 - HOOPER HOLMES INCexhibit992pressrelease.htm
EX-23.1 - EXHIBIT 23.1 - HOOPER HOLMES INCexhibit231rsmconsent.htm
EX-10.10 - EXHIBIT 10.10 - HOOPER HOLMES INCexhibit1010optionawardagre.htm
EX-10.9 - EXHIBIT 10.9 - HOOPER HOLMES INCexhibit109optionawardagree.htm
EX-10.8 - EXHIBIT 10.8 - HOOPER HOLMES INCexhibit108subordinatedprom.htm
EX-10.7 - EXHIBIT 10.7 - HOOPER HOLMES INCexhibit107votingstandstill.htm
EX-10.6 - EXHIBIT 10.6 - HOOPER HOLMES INCexhibit106securitiespurcha.htm
EX-10.5 - EXHIBIT 10.5 - HOOPER HOLMES INCexhibit105securitiespurcha.htm
EX-10.4 - EXHIBIT 10.4 - HOOPER HOLMES INCexhibit104joinderagreement.htm
EX-10.3 - EXHIBIT 10.3 - HOOPER HOLMES INCexhibit103sideletter.htm
EX-10.2 - EXHIBIT 10.2 - HOOPER HOLMES INCexhibit102guarantyagreemen.htm
EX-10.1 - EXHIBIT 10.1 - HOOPER HOLMES INCexhibit101amendedrestatedc.htm
EX-4.4 - EXHIBIT 4.4 - HOOPER HOLMES INCexhibit44commonstockpurcha.htm
EX-4.3 - EXHIBIT 4.3 - HOOPER HOLMES INCexhibit43commonstockpurcha.htm
EX-4.2 - EXHIBIT 4.2 - HOOPER HOLMES INCexhibit42commonstockpurcha.htm
EX-4.1 - EXHIBIT 4.1 - HOOPER HOLMES INCexhibit41secondamendedrest.htm
8-K - 8-K - HOOPER HOLMES INChhform8-kreclosingofmerger.htm
(OTCQX: HPHW) Earnings Presentation Speakers: Henry Dubois, Chief Executive Officer Steven Balthazor, Chief Financial Officer

Safe Harbor 2 Special Note Regarding Forward-Looking Statements This presentation contains forward-looking statements, as such term is defined in the Private Securities Litigation Reform Act of 1995, concerning the Company’s plans, objectives, goals, strategies, future events or performances, which are not statements of historical fact and can be identified by words such as: “expect,” “continue,” “should,” “may,” “will,” “project,” “anticipate,” “believe,” “plan,” “goal,” and similar references to future periods. The forward-looking statements contained in this presentation reflect our current beliefs and expectations. Actual results or performance may differ materially from what is expressed in the forward looking statements. Among the important factors that could cause actual results to differ materially from those expressed in, or implied by, the forward- looking statements contained in this presentation are our ability to realize the expected synergies and other benefits from our merger with Provant Health Solutions; our ability to realize the expected benefits from the acquisition of Accountable Health Solutions and our strategic alliance with Clinical Reference Laboratory; our ability to successfully implement our business strategy and integrate Accountable Health Solutions’ and Provant Health Solutions’ business with ours; our ability to retain and grow our customer base; our ability to recognize operational efficiencies and reduce costs; uncertainty as to our working capital requirements over the next 12 to 24 months; our ability to maintain compliance with the financial covenants contained in our credit facilities; the rate of growth in the Health and Wellness market and such other factors as discussed in Part I, Item 1A, Risk Factors, and Part II, Item 7, Management’s Discussion and Analysis of Financial Conditions and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2016. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances, or to reflect the occurrence of unanticipated events, after the date of this presentation, except as required by law. This presentation contains information from third-party sources, including data from studies conducted by others and market data and industry forecasts obtained from industry publications. Although the Company believes that such information is reliable, the Company has not independently verified any of this information and the Company does not guarantee the accuracy or completeness of this information. Any references to documents not included in the presentation itself are qualified by the full text and content of those documents. During our prepared comments or responses to your questions, we may offer incremental metrics to provide greater insight into the dynamics of our business or our quarterly results, such as references to EBITDA, adjusted EBITDA and other measures of financial performance. Please be advised that this additional detail may be one-time in nature and we may or may not provide an update in the future. These and other financial measures may also have been prepared on a non-GAAP basis.

3 Merger Closed One of the largest pure-play Health & Wellness companies Enhanced Financial Model › $67 + million in 2016 pro-forma revenue › $54 + million revenue target for Q2 – Q4 2017 › $ 3 + million adjusted EBITDA target for Q2 – Q4 2017 › $ 5 + million adjusted EBITDA target for 2018 › $ 7 million annualized synergy savings Stronger Operating Position › On-site screenings, risk assessments and immunizations › Technology platform capabilities and coaching › Engagement and advanced data management

4 Standalone Q1 Revenue Results - Hooper Holmes Q1 Year-Over-Year Revenue Improvements › 5% revenue growth to $7.6 million › 44% growth in channel partner and clinical research organization revenue › 33% growth in channel partner revenue › 166% growth in clinical research organization revenue › 16% gross margin improvement Gross Margin ($mm) +16% +5% Overall $7.24 Revenue ($mm) +33% Channel

5 Adjusted EBITDA ($000’s) › 28% Improvement in Adjusted EBITDA › 26% Improvement in Net Loss › SG&A Improved 9% Improved Q1 Operating Performance - Hooper Holmes +26% Net Loss ($000’s) Excluding transaction costs +28% Adjusted EBITDA ($000’s) Q1 2016 Q1 2017 Net Los (3,428) (3,129) Transaction Costs 108 682 Net Loss Excluding Transaction Cost (3,320) (2,447) Interest expense $212 $219 Other Debt related costs in Int exp $577 $548 Income taxes $5 $5 Depreciation & amortization $701 $623 Stock Payments $230 $38 Transition Costs $52 ($2) Leases/Ornelas settlements $150 $19 Adjusted EBITDA ($1,393) ($997)

6 Stronger Capital Structure - Merged Company Shares Outstanding Shares (mm) Pre-Transaction 10.5 › Shares Issued to Provant shareholders 10.5 › $3.5mm Capital Raise from various investors (raised at $0.80 / share; final $280k within 90 days) 4.3 › Transaction fees to be paid in equity 0.6 Pro-forma shares outstanding post transaction close 25.9 Revolver $ mm Total availability (with flexibility to draw additional $5mm with sufficient accounts receivable) $10.0 - $15.0 › Amount drawn at close $6.3 › Access to additional seasonal credit facility $2.0 Term Debt $ mm Total $6.5 › Repays existing term facility, provide working capital › Principal payment holiday for 18 months

7 Synergies Driven by Integration - Merged Company Health Professional Network Expansion Q2 2017 Q3 2017 Q4 2017 Q1 2018 Enhanced Coaching Capabilities Technology & Infrastructure Operations Efficiencies Duplicative SG&A Screening, clinical, and coaching efficiencies Realization of technology platform capacity $7 million Annualized Cost Efficiencies New sales with an annualized value of $5.5 million in Q1 Growth in Sales Integration Drives Customer Benefits and Operations Improvements 20% already achieved  $0.7 million in new contracts from existing channel partners.  $1.6 million from new direct customers.  $3.2 million from new channel partners.

8 2017 Outlook - Merged Company Advanced and scalable data hub technology Diversified sales channels Expanded management team Infrastructure to Accelerate Growth Improved cost structure with shift towards higher margin, recurring revenue mix (e.g., Portal & Coaching) Increased scale provides operating leverage Enhanced innovation and speed to market Road Map to Profitability Targets $ 3 + million adjusted EBITDA for Q2 – Q4 2017 $ 7 million annualized synergy savings $ 5 + million adjusted EBITDA for 2018 Positive 2018 Net Income $54 million revenue for Q2 - Q4 2017